Azenta Q4 Adjusted EPS of 28 Cents Nearly Triples the 11-Cent Consensus
AZTA has more than doubled off its 52-week low of $15.93.
Summary
Azenta closed fiscal 2026 with adjusted EPS of 28 cents a share, well above the 11-cent consensus and up from 21 cents a year earlier. Revenue rose 5% to $167.09 million, topping the $160.13 million analysts expected, and GAAP net income came in at $6.79 million, or 16 cents a share. The beat lands after a rough stretch of estimate cuts — the mean earnings estimate fell about 34% over the past three months and three analysts revised lower in the last 30 days — so the bar was low. It also follows the October 7 restructuring of the Multiomics segment, which closed three North American labs and cut jobs, and the August CEO transition to interim chief Dr. Martin Madaus. The stock is trading near its 52-week high of $46.41, and the median analyst price target of $38.50 sits below the last close of $40.95, so the beat has to carry the multiple from here.
At the time of this announcement, AZTA was trading at $44.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $15.93 to $46.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.